Neil Bhattacharyya1. 1. Division of Otolaryngology, Brigham and Women's Hospital, 333 Longwood Ave, Boston, MA 02115, USA.
Abstract
OBJECTIVE: To determine factors that affect survival in patients with Hürthle cell carcinoma of the thyroid gland. METHODS: Data for all cases of Hürthle cell carcinoma that occurred between January 1, 1988, and December 31, 1998, were extracted from the Surveillance, Epidemiology, and End Results database. Clinical data regarding age, sex, tumor size, primary site extension, nodal involvement, and vital status were tabulated. Patients with distant metastases were excluded, and Kaplan-Meier survival analysis was conducted. Survival data for patients with Hürthle cell carcinoma were compared with data for a control group of patients with follicular cell carcinoma matched for age, sex, tumor size, and local disease extension. Cox multivariate regression analysis was conducted to determine the effect of predictor variables on overall survival in Hürthle cell carcinoma. RESULTS: We identified 555 cases of nonmetastatic Hürthle cell carcinoma (mean age at diagnosis, 55.9 years; women, 67.9%). The primary tumor was intrathyroidal in 83.8% of patients, whereas 11.2% had minor local extension. Mean tumor size was 3.5 cm. Mean, 5-year, and 10-year survival for Hürthle cell carcinoma was 109 months, 85.1%, and 71.1%, respectively. Mean survival for 411 matched patients with follicular cell carcinoma was 113 months, which was not statistically different from that of patients with Hürthle cell carcinoma (P =.47, log-rank test). On multivariate analysis, increasing age at diagnosis, male sex, and increasing tumor size were statistically significant predictors of poor survival; degree of primary site extension did not affect survival. CONCLUSIONS: Overall survival for Hürthle cell carcinoma is similar to that of comparably staged follicular cell carcinoma. Increasing age, male sex, and increasing tumor size substantially diminish survival in patients with Hürthle cell carcinoma.
OBJECTIVE: To determine factors that affect survival in patients with Hürthle cell carcinoma of the thyroid gland. METHODS: Data for all cases of Hürthle cell carcinoma that occurred between January 1, 1988, and December 31, 1998, were extracted from the Surveillance, Epidemiology, and End Results database. Clinical data regarding age, sex, tumor size, primary site extension, nodal involvement, and vital status were tabulated. Patients with distant metastases were excluded, and Kaplan-Meier survival analysis was conducted. Survival data for patients with Hürthle cell carcinoma were compared with data for a control group of patients with follicular cell carcinoma matched for age, sex, tumor size, and local disease extension. Cox multivariate regression analysis was conducted to determine the effect of predictor variables on overall survival in Hürthle cell carcinoma. RESULTS: We identified 555 cases of nonmetastatic Hürthle cell carcinoma (mean age at diagnosis, 55.9 years; women, 67.9%). The primary tumor was intrathyroidal in 83.8% of patients, whereas 11.2% had minor local extension. Mean tumor size was 3.5 cm. Mean, 5-year, and 10-year survival for Hürthle cell carcinoma was 109 months, 85.1%, and 71.1%, respectively. Mean survival for 411 matched patients with follicular cell carcinoma was 113 months, which was not statistically different from that of patients with Hürthle cell carcinoma (P =.47, log-rank test). On multivariate analysis, increasing age at diagnosis, male sex, and increasing tumor size were statistically significant predictors of poor survival; degree of primary site extension did not affect survival. CONCLUSIONS: Overall survival for Hürthle cell carcinoma is similar to that of comparably staged follicular cell carcinoma. Increasing age, male sex, and increasing tumor size substantially diminish survival in patients with Hürthle cell carcinoma.
Authors: Vera Wenter; Annamirl Jellinek; Marcus Unterrainer; Freba Ahmaddy; Sebastian Lehner; Nathalie Lisa Albert; Peter Bartenstein; Thomas Knösel; Christine Spitzweg; Harun Ilhan; Andrei Todica Journal: Eur J Nucl Med Mol Imaging Date: 2019-08-13 Impact factor: 9.236
Authors: A Barnabei; E Ferretti; R Baldelli; A Procaccini; G Spriano; M Appetecchia Journal: Acta Otorhinolaryngol Ital Date: 2009-12 Impact factor: 2.124
Authors: Andrés Coca-Pelaz; Juan P Rodrigo; Jatin P Shah; Alvaro Sanabria; Abir Al Ghuzlan; Carl E Silver; Ashok R Shaha; Peter Angelos; Dana M Hartl; Antti A Mäkitie; Kerry D Olsen; Randall P Owen; Gregory W Randolph; Ricard Simó; Ralph P Tufano; Luiz P Kowalski; Mark E Zafereo; Alessandra Rinaldo; Alfio Ferlito Journal: Adv Ther Date: 2021-08-22 Impact factor: 3.845